Enzymatic debrider

Wound debridement using traditional larval (‘maggot’) therapy has well established clinical benefits and is recognised as a highly effective debridement tool. It is particularly effective against wound pathogens e.g. MRSA and is reported to be a mainly pain-free debridement technique.

The aim of this program is to develop a product with the following target profile:

• Deliver the same, effective enzymes as deployed within maggot therapy without direct administration of the maggots themselves
• A novel debrider using recombinant maggot enzymes with a similar efficacy profile to the larval product
• Topical & non-invasive product debridement technique
• Superior efficacy to established topical debriders
• Enzymes incorporated into hydrogel during manufacture retain their protease activity and deliver enzyme activity for at least seven days
• Convenient to use and well tolerated (i.e. pain-free)

Status of development

• Recently completed a Grant-funded research program
• Product being developed in collaboration with a leading academic group from the University of Nottingham, UK
• Early results demonstrate that active enzymes can be released from AGTS’s carrier
• IP on this novel & innovative delivery of recombinant enzyme has been filed
• Prototype viscous gel/lotion developed
• Has demonstrated superior performance to current market leader Santyl® (Healthpoint)